Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 1.00 |
| ▸ | NPC1 | O15118 | 12/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381573 | 0.89 | RAB9A (0.80) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL18027795 | 0.83 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL2490566 | 0.82 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL12764167 | 0.82 | GRM4 (0.72) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL259290 | 0.81 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL11903751 | 0.81 | KMT2A (0.70) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL19376801 | 0.78 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL7718028 | 0.77 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL18993406 | 0.77 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL23012153 | 0.77 | GRM4 (0.73) | RAB9ANPC1SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906522-B2 | 2-aminoquinazoline derivatives | KYOWA HAKKO KIRIN CO., LTD (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | SLC7A1, SLC38A7, PRMT7 | RAB9A 112/4885NPC1 2386/4885SMN1; SMN2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.